Investment Profile

The primary focus of the Group’s activities is on projects with an anticipated 4-6 year development track from their inception to commercialization.

Adiuvo’s business model includes the validation of non-medicinal products using procedures to obtain data that make it possible to confirm pro-health effects, enhance treatment outcomes, or prevent the progression of a disease. Such products can be sold with confirmed health indications (nutraceuticals) or certificates permitting their use by patients (patient monitoring) after the performance of clinical studies.

This, along with protected intellectual property rights, provides the Company with competitive advantages and, as a result, attracts the interest of leaders in the sector.

Currently, Adiuvo is developing more than 25 projects by means of two platforms:

Nutraceuticals Platform

Medical Devices and Digital Health Platform

Find us on